A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.

One company holds a near-total monopoly on it.

Daniel Alkon Biography and Net Worth

Insider of Synaptogenix

Dr. Alkon has served as President and Chief Scientific Officer of Synaptogenix since September 2016 and the Founding Chief Scientific Officer since 2012 . A leader in the field, Dr. Alkon comes to Synaptogenix after 30 years directing programs on the molecular basis of associative memory at the National Neurologic Institute of NIH, and another 15 years as the Founding Scientific Director of the Blanchette Rockefeller. Neuroscience Institute where he and his team developed neurorestorative therapeutics for degenerative disorders of the central nervous system. He also served as the Toyota Chair of Neurodegenerative Diseases and Professor of Neurology at West Virginia University and Research Professor of Biophysics at Johns Hopkins University before joining Synaptogenix.

An internationally recognized pioneer in research on brain-based neural networks, the molecular basis of memory, and degenerative brain disorders, he has authored hundreds of scientific articles as well as several books, including Memory Traces in the Brain by Cambridge University Press, and the popular book Memory’s Voice by Harper Collins.

Dr. Alkon received his B.A. from the University of Pennsylvania, and his M.D. at Cornell University, after which he interned at the Mt Sinai Hospital in New York.

What is Daniel L. Alkon's net worth?: The estimated net worth of Daniel L. Alkon is at least $7,232.89 as of December 16th, 2022. Dr. Alkon owns 1,421 shares of Synaptogenix stock worth more than $7,233 as of May 6th. This net worth approximation does not reflect any other assets that Dr. Alkon may own. Additionally, Dr. Alkon receives a salary of $375,000.00 as Insider at Synaptogenix. Learn More about Daniel L. Alkon's net worth.
How old is Daniel L. Alkon?: Dr. Alkon is currently 82 years old. There are 2 older executives and no younger executives at Synaptogenix. Learn More on Daniel L. Alkon's age.
What is Daniel L. Alkon's salary?: As the Insider of Synaptogenix, Inc., Dr. Alkon earns $375,000.00 per year. The highest earning executive at Synaptogenix is Mr. Robert Weinstein, CFO, Executive VP, Treasurer & Secretary, who commands a salary of $568,920.00 per year. Learn More on Daniel L. Alkon's salary.
How do I contact Daniel L. Alkon?: The corporate mailing address for Dr. Alkon and other Synaptogenix executives is 1185 AVENUE OF THE AMERICAS 3RD FLOOR, NEW YORK NY, 10036. Synaptogenix can also be reached via phone at 973-242-0005 and via email at [email protected]. Learn More on Daniel L. Alkon's contact information.
Has Daniel L. Alkon been buying or selling shares of Synaptogenix?: Daniel L. Alkon has not been actively trading shares of Synaptogenix within the last three months. Most recently, Daniel L. Alkon sold 787 shares of the business's stock in a transaction on Friday, December 16th. The shares were sold at an average price of $29.25, for a transaction totalling $23,019.75. Following the completion of the sale, the insider now directly owns 1,421 shares of the company's stock, valued at $41,564.25. Learn More on Daniel L. Alkon's trading history.

Daniel L. Alkon Insider Trading History at Synaptogenix

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/16/2022	Sell	787	$29.25	$23,019.75	1,421
6/14/2021	Buy	400	$206.50	$82,600.00	459

Daniel L. Alkon Buying and Selling Activity at Synaptogenix

Synaptogenix Company Overview

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. The company was incorporated in 2012 and is headquartered in New York, New York.

Today's Range

Now: $5.09

$4.72

$5.38

50 Day Range

MA: $4.75

$4.33

$5.44

2 Week Range

Now: $5.09

$3.53

$47.00

Volume

165,100 shs

Average Volume

46,176 shs

Market Capitalization

$5.55 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.25

Elon to Transform U.S. Economy?

From Porter & Company | Ad